^
    Back
    Association details:
    Biomarker:HER-2 expression
    Cancer:Uterine Cancer
    Drug:Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Solid Tumor)
    New
    Title:

    ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors

    Excerpt:
    ...ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2021
    Title:

    813P - Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma (STATICE trial, NCCH1615): A multicenter, phase II clinical trial

    Published date:
    09/13/2021
    Excerpt:
    The number of responders (CR and PR) was 12 (55%), stable disease (SD) was 10 (45%) and no PD (0%) in HER2 2+/3+...The median PFS in HER2 2+/3+ was 6.2 (95% CI; 4.0-8.8) months….The STATICE trial met the primary objective of ORR in HER2 2+/3+ unresectable UCS.